{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:53:26Z","timestamp":1793912006991,"version":"4.8.0"},"reference-count":27,"publisher":"American Chemical Society (ACS)","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP210101496"],"award-info":[{"award-number":["DP210101496"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","award":["AQIRF094-2023RD6"],"award-info":[{"award-number":["AQIRF094-2023RD6"]}],"id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of mRNA therapies has innovated the clinical progress of cancer immunotherapy. However, current immunotherapeutic approaches are unable to achieve site- or immune-cell-specific delivery, resulting in adverse immune responses in off-target tissues. In addition, the commercial lipid nanoparticle (LNP) formulations with a poly(ethylene glycol) coating generally undergo significant hepatic accumulation during clearance. To promote site- and immune-cell-specific delivery of therapeutic mRNA-LNPs, we investigated several bioconjugation approaches to attach targeting antibodies onto the surface of polymer-functionalized mRNA-LNPs. Building on our previous work, side-chain sulfoxide polymer\u2013lipid conjugate PMSEA-DSPE was used to incorporate a low-fouling polymeric LNP coating. trans-Cyclooctene functionality was incorporated within PMSEA-DSPE end groups to allow conjugation to the tetrazine-functionalized nanobody 9G8 for EGFR targeting. Bioconjugation methods were compared, including direct conjugation and post-insertion. The results showed that 9G8-attached PMSEA mRNA-LNPs prepared via direct conjugation significantly enhanced cell association and in vitro transfection efficiency with an EGFR-positive cell line, demonstrating the potency of active targeting for mRNA-LNP platforms with side-chain polymer coatings.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00045","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:12:23Z","timestamp":1774519943000},"page":"684-692","source":"Crossref","is-referenced-by-count":6,"title":["Lipid Nanoparticles\nwith Side-Chain Polymer Coating\nfor Targeted mRNA Delivery through Nanobody Attachment"],"prefix":"10.1021","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-7797","authenticated-orcid":true,"given":"On Ting","family":"Choy","sequence":"first","affiliation":[{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-833X","authenticated-orcid":true,"given":"Nicholas L.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]},{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]},{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-4993","authenticated-orcid":true,"given":"Pie","family":"Huda","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]},{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]},{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2795","authenticated-orcid":true,"given":"Craig A.","family":"Bell","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]},{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9165-1540","authenticated-orcid":true,"given":"David J.","family":"Owen","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]},{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-8355","authenticated-orcid":true,"given":"Andrew K.","family":"Whittaker","sequence":"additional","affiliation":[{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]},{"name":"The University of Queensland , , , ,","place":["Brisbane, Queensland, Australia, 4072"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"4","key":"2026100504065853700_cit1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2500\na new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"6","key":"2026100504065853700_cit2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical\nprogress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"2026100504065853700_cit3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects\nof mRNA-based\ndrugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduction Targeted Ther."},{"issue":"15sup","key":"2026100504065853700_cit4","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A phase I multicenter\nstudy to assess the safety, tolerability, and immunogenicity of mRNA-4157\nalone in patients with resected solid tumors and in combination with\npembrolizumab in patients with unresectable solid tumors","volume":"37","author":"Burris","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10427","key":"2026100504065853700_cit5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab\nversus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942):\na randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"16sup","key":"2026100504065853700_cit6","doi-asserted-by":"publisher","first-page":"TPS9616","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9616","article-title":"INTerpath-001: Pembrolizumab with V940 (mRNA-4157)\nversus pembrolizumab with placebo for adjuvant treatment of high-risk\nstage II-IV melanoma","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"2026100504065853700_cit7","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles\nfor mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nature Reviews Materials"},{"issue":"7","key":"2026100504065853700_cit8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics\nWith Endogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"2026100504065853700_cit9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression\nkinetics of nucleoside-modified mRNA delivered in lipid nanoparticles\nto mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Controlled Release"},{"issue":"21","key":"2026100504065853700_cit10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe\ncytokine release syndrome after CD19 chimeric antigen receptor-modified\nT-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2026100504065853700_cit11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury\ninduced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"7","key":"2026100504065853700_cit12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/ph15070897","article-title":"The Future\nof Tissue-Targeted Lipid\nNanoparticle-Mediated Nucleic Acid Delivery","volume":"15","author":"Kularatne","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"2026100504065853700_cit13","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene Glycol Immunogenicity:\nTheoretical, Clinical, and Practical Aspects of Anti-Polyethylene\nGlycol Antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"2026100504065853700_cit14","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41563-024-02116-3","article-title":"High-density brush-shaped polymer\nlipids reduce anti-PEG\nantibody binding for repeated administration of mRNA therapeutics","volume":"24","author":"Xiao","year":"2025","journal-title":"Nat. Mater."},{"key":"2026100504065853700_cit15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124695","article-title":"Replacing poly(ethylene\nglycol) with\nRAFT lipopolymers in mRNA lipid nanoparticle systems for effective\ngene delivery","volume":"665","author":"Hassanel","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"7","key":"2026100504065853700_cit16","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1021\/acs.biomac.4c00651","article-title":"Tailored Monoacyl\nPoly(2-oxazoline)- and Poly(2-oxazine)-Lipids as PEG-Lipid Alternatives\nfor Stabilization and Delivery of mRNA-Lipid Nanoparticles","volume":"25","author":"He","year":"2024","journal-title":"Biomacromolecules"},{"key":"2026100504065853700_cit17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1021\/acs.biomac.5c01899","article-title":"PEG-free\nLipid Nanoparticles for\nmRNA Delivery: Superhydrophilic Sulfoxide Polymer Coatings","volume":"27","author":"Choy","year":"2026","journal-title":"Biomacromolecules"},{"issue":"7","key":"2026100504065853700_cit18","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid\nNanoparticles","volume":"9","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"issue":"11","key":"2026100504065853700_cit19","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+\nT cell targeting and genetic recombination using engineered CD4+ cell-homing\nmRNA-LNPs","volume":"29","author":"Tomba\u0301cz","year":"2021","journal-title":"Mol. Ther."},{"key":"2026100504065853700_cit20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","article-title":"A versatile antibody\ncapture system drives specific\nin vivo delivery of mRNA-loaded lipid nanoparticles","volume":"20","author":"Chen","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"2026100504065853700_cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102520","article-title":"Targeted mRNA delivery with bispecific antibodies that\ntether LNPs to cell surface markers","volume":"36","author":"Dietmair","year":"2025","journal-title":"Mol. Ther\nNucleic Acids"},{"issue":"2","key":"2026100504065853700_cit22","doi-asserted-by":"publisher","DOI":"10.1002\/cmtd.202300036","article-title":"Click-on Antibody Fragments for Customisable\nTargeted\nNanomedicines \u2013 Site-specific Tetrazine and Azide Functionalisation\nthrough Non-canonical Amino Acid incorporation","volume":"4","author":"Huda","year":"2024","journal-title":"Chemistry Methods"},{"issue":"1","key":"2026100504065853700_cit23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1021\/acs.biomac.5c01899","article-title":"PEG-free\nLipid Nanoparticles for\nmRNA Delivery: Superhydrophilic Sulfoxide Polymer Coatings","volume":"27","author":"Choy","year":"2026","journal-title":"Biomacromolecules"},{"issue":"13","key":"2026100504065853700_cit24","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1021\/ma062919u","article-title":"Thiocarbonylthio\nEnd Group Removal from RAFT-Synthesized Polymers by Radical-Induced\nReduction","volume":"40","author":"Chong","year":"2007","journal-title":"Macromolecules"},{"issue":"4","key":"2026100504065853700_cit25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/acschembio.0c00003","article-title":"Engineering Caveolae-Targeted\nLipid\nNanoparticles To Deliver mRNA to the Lungs","volume":"15","author":"Li","year":"2020","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"2026100504065853700_cit26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform\nfor targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"24","key":"2026100504065853700_cit27","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202500605","article-title":"Nanobody-Decorated\nLipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo","volume":"14","author":"Escude\u0301 Martinez de Castilla","year":"2025","journal-title":"Advanced Healthcare Materials"}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00045","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/4\/684\/68742919\/acs.bioconjchem.6c00045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/4\/684\/68742919\/acs.bioconjchem.6c00045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:11:36Z","timestamp":1791187896000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/4\/684\/5137604\/Lipid-Nanoparticles-with-Side-Chain-Polymer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,4,15]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00045","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}